悦康药业(688658) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was RMB 1,128,554,211.20, representing a year-on-year increase of 25.28%[3] - The net profit attributable to shareholders for Q1 2023 was RMB 85,267,722.97, reflecting a growth of 34.35% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 83,120,811.26, which is an increase of 45.79% year-on-year[3] - The total operating profit for Q1 2023 reached CNY 96,308,524.11, up from CNY 64,302,047.67 in the same period last year, reflecting a growth of 49.83%[34] - The net profit for Q1 2023 was CNY 85,532,999.31, an increase of 33.73% compared to CNY 63,971,233.59 in Q1 2022[34] - The company reported a total comprehensive income attributable to shareholders of the parent company of CNY 85,267,722.97, compared to CNY 63,467,735.64 in the previous year, marking a 34.36% increase[35] Earnings and Shares - The basic earnings per share for Q1 2023 was RMB 0.19, an increase of 35.71% year-on-year[22] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.19, up from CNY 0.14 in Q1 2022, representing a growth of 35.71%[35] - The number of common shareholders at the end of the reporting period was 12,994[8] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 5,400,000 shares[27] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was RMB 217,240,051.53, with no applicable year-on-year comparison[3] - Cash flow from operating activities for Q1 2023 was CNY 217,240,051.53, a significant improvement from a negative cash flow of CNY -32,912,014.96 in Q1 2022[36] - The company generated CNY 1,245,924,747.38 in cash inflows from operating activities, compared to CNY 1,099,933,827.58 in the previous year, indicating a growth of 13.27%[36] - The cash outflow from investing activities in Q1 2023 was CNY 120,799,575.39, compared to CNY 174,648,539.72 in Q1 2022, showing a decrease of 30.77%[37] - The net cash flow from financing activities for Q1 2023 was CNY -4,941,579.45, an improvement from CNY -9,086,512.50 in Q1 2022[37] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to RMB 6,274,070,620.90, a 4.42% increase from the end of the previous year[22] - Current liabilities rose to CNY 2,075,463,910.81, compared to CNY 1,899,350,053.82, reflecting an increase of about 9.29%[43] - Total liabilities reached CNY 2,182,169,374.02, an increase from CNY 2,011,390,540.27, indicating a growth of approximately 8.50%[43] - The company's equity attributable to shareholders increased to CNY 4,083,294,565.44 from CNY 3,988,972,492.50, marking a rise of about 2.37%[43] - Total assets increased to CNY 6,274,070,620.90, up from CNY 6,008,455,853.38, representing a growth of approximately 4.43%[42] Research and Development - The total R&D investment for Q1 2023 was RMB 88,048,480.27, which decreased by 18.09% compared to the same period last year[22] - R&D investment accounted for 7.80% of operating revenue, down 4.13 percentage points year-on-year[22] - Research and development expenses for Q1 2023 amounted to CNY 73,728,143.73, slightly down from CNY 73,938,790.33 in Q1 2022[33] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[33] Other Financial Metrics - The total operating costs for Q1 2023 were CNY 1,026,297,006.75, compared to CNY 841,629,577.42 in Q1 2022, indicating an increase of about 22%[33] - Tax and additional charges for Q1 2023 were CNY 13,235,710.21, compared to CNY 9,500,921.39 in Q1 2022, showing an increase of about 39%[33] - The company recorded a foreign exchange gain of CNY 1,739,256.84 in Q1 2023, contrasting with a loss of CNY -246,411.32 in the same period last year[37] - The company has ongoing development expenditures amounting to CNY 203,971,423.01, up from CNY 194,082,152.08, indicating an increase of approximately 5.00%[42]